Calamos Advisors LLC Has $13.92 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Calamos Advisors LLC lessened its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 182,573 shares of the medical research company’s stock after selling 3,080 shares during the quarter. Calamos Advisors LLC’s holdings in Edwards Lifesciences were worth $13,921,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in EW. Advisors Asset Management Inc. lifted its position in shares of Edwards Lifesciences by 0.3% during the 1st quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock worth $5,127,000 after buying an additional 117 shares during the period. Apollon Wealth Management LLC increased its holdings in Edwards Lifesciences by 1.0% during the 1st quarter. Apollon Wealth Management LLC now owns 12,487 shares of the medical research company’s stock valued at $1,033,000 after purchasing an additional 119 shares in the last quarter. Geller Advisors LLC raised its position in Edwards Lifesciences by 6.5% in the 1st quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock valued at $231,000 after purchasing an additional 120 shares during the last quarter. Legacy Wealth Asset Management LLC grew its holdings in shares of Edwards Lifesciences by 0.8% during the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock worth $1,293,000 after purchasing an additional 134 shares during the last quarter. Finally, KCM Investment Advisors LLC increased its stake in shares of Edwards Lifesciences by 2.7% in the first quarter. KCM Investment Advisors LLC now owns 5,392 shares of the medical research company’s stock valued at $635,000 after buying an additional 142 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the completion of the sale, the vice president now owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at $16,049,739.68. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total value of $944,130.00. Following the transaction, the vice president now directly owns 39,503 shares in the company, valued at $3,390,542.49. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock valued at $17,166,254 in the last ninety days. 1.29% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on EW shares. Citigroup boosted their target price on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Wells Fargo & Company upgraded shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective on the stock in a report on Friday, February 2nd. Morgan Stanley raised their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. Finally, Mizuho increased their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $91.73.

Edwards Lifesciences Stock Performance

NYSE EW traded down $0.06 on Friday, hitting $86.39. 404,510 shares of the stock were exchanged, compared to its average volume of 3,818,674. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $96.12. The business’s fifty day moving average is $90.14 and its 200 day moving average is $78.19. The company has a market capitalization of $52.00 billion, a PE ratio of 37.59, a P/E/G ratio of 4.32 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting the consensus estimate of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The business had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter in the prior year, the business posted $0.64 earnings per share. Edwards Lifesciences’s revenue was up 13.3% compared to the same quarter last year. Research analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.